Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ethoxzolamide, dichlorphenamide, topiramate +8 | 1.00 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 3 stopped | 0.52 |
| literature PubMed | 1,409 Parkinson's papers of 242,190: well-trodden | 0.05 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2717
Sealed predictions
- CA2 in dopamine neurons, braak-0.05 (p 0.889) → +0.05 (p 0.907)receipt 2725
Swarm cases
receipt 2725: CA2 in dopamine neurons, braak
- power
- full sample +0.19 (p 0.455, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.369, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.265, n 18). could be the mix.
- skeptic
- leave-one-out range +0.08 to +0.30, sign flips 0; without severely affected donors +0.19 (p 0.455, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CA2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts